<DOC>
	<DOCNO>NCT02124161</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety 13-valent pneumococcal polysaccharide vaccine give concomitantly seasonal inactivated influenza vaccine adult 50 year old previously receive 23-valent pneumococcal polysaccharide vaccine .</brief_summary>
	<brief_title>Concomitant Administration 13-valent Pneumococcal Conjugate Vaccine ( 13vPnC ) With Influenza Vaccine 23-valent Pneumococcal Polysaccharide ( 23vPS ) Pre-vaccinated Adults .</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>1 . Evidence personally sign date informed consent document ( ICD ) indicate subject inform pertinent aspect study . 2 . Male female adult 50 year age old . 3 . Documented vaccination 1 prior dos 23vPS , last give least 1 year prior study enrollment . 4 . Negative urine pregnancy test female subject child bear potential . 1 . Previous vaccination Prevnar® , Prevnar 13® , investigational pneumococcal conjugate vaccine . 2 . History severe adverse reaction associate vaccine vaccinerelated component . 3 . Allergic egg protein ( egg egg product ) chicken protein . 4 . History GuillainBarré syndrome . 5 . Vaccination influenza vaccine within 6 month ( 182 day ) investigational product administration . 6 . Documented S pneumoniae infection within past 5 year investigational product administration .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pneumococcal polysaccharide vaccine</keyword>
	<keyword>13-valent pneumococcal conjugate vaccine</keyword>
	<keyword>invasive pneumococcal disease</keyword>
	<keyword>flu vaccine</keyword>
</DOC>